Fangsheng Pharmaceutical announced that the company disclosed operating data for the first three quarters of 2026. The industrial subtotal revenue was 1,299 million yuan, up 12.45% year on year; the revenue for cardiovascular and cerebrovascular disease drugs was 635 million yuan, up 46.25% year on year; and revenue in South China was 205 million yuan, up 86.53% year on year. The medical business and other operating income was 43.9389 million yuan, a year-on-year decrease of 15.06%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.